Medtech Connect brings together the most innovative startups, visionary medtech investors and largest medical technology providers. The event is a platform designed to stimulate growth and explore how businesses can take the leap to the next generation of highly impactful clinical products and services.
Medtech Connect Singapore 2021 explored the opportunities for medtech innovation in APAC in a COVID-19 impacted world. This webinar features VCs representing the Japanese, Australian, Singaporean and Chinese market discussing the trends and challenges in their markets respectively for the years to come. Bringing together innovative start-ups, medical technology providers and medtech investors from across the globe to debate these key issues and share their insights.
Speakers
Yan Lin Lye | Head of medtech APAC, Cambridge Consultants
Yan Lin has spent over 10 years working in and with start ups across the world to help commercialise their cutting edge technology. She currently leads Cambridge Consultants MedTech commercial activity in APAC.
Hsien-Hui Tong | Executive Director – Investments for SGInnovate
Hsien-Hui brings with him in-depth knowledge and experience in the Business Development and Venture Capital spaces across Australia, Europe, Singapore and the US. As the Executive Director of Investments, Hsien-Hui leads SGInnovate's investments efforts, from working with research scientists to create and launch venture-fundable solutions based on their Deep Tech research core, to identifying high-potential, Deep Tech startups working on areas such as Artificial Intelligence, Autonomous Vehicles, Advanced Manufacturing, AgriFoodTech, MedTech and Quantum Computing.
Brian Hakim | Director of International Business Development for MedTecX
Brian is the Director of International Business Development for the China-based device accelerator, MedTecX, and a founder of the investment consulting firm, ECM Medical. Previously, he had roles at Medtronic, BioCardia, IsoStent, Velomedix, and Baxter Healthcare and has an engineering master’s degree from the University of Minnesota and an MBA from the Kellogg School of Management.
Helen Fisher | MD and CEO, Bio Capital Impact Fund
Helen is CEO and Managing Director of Bio Capital Impact Fund (BCIF) and a non-executive director and the Chair of the Audit and Risk Management Committees of Calix Limited (ASX:CXL) and Paradigm Biopharmaceuticals Limited (ASX:PAR). She was a non-executive director of BARD1 Life Sciences Ltd (ASX:BD1), a cancer diagnostics company, and a director and the Chair of the Audit and Risk Committee at Sienna Cancer Diagnostics (ASX:SDX) before it was acquired by BARD1. She is also the Chair of the Victorian branch of AusBiotech.
Prior to establishing BCIF, Helen was a partner of Deloitte and led Deloitte’s life sciences practice in Australia for 5 years, having had many years’ experience in the life sciences and health care sector. She also specialised in the financial services sector, servicing some of the large banks and funds and has been involved in setting up a number of large international funds, as well as advised on a number of significant M&A transactions.
Helen has Bachelor degrees in Law (with honours) and Science from the University of Melbourne, a Masters degree in Laws (specialising in International Taxation) from the University of Melbourne and a Masters degree in Commerce from the University of NSW.
Ryuta Takeda | Global Bridge Research Center, Director, Leave a Nest Co., Ltd.
Ryuta Takeda received Ph.D. from The Ohio State University, and trained as a pure scientist in a biotech field. After joining Leave a Nest, he initiated “TECH PLANTER” in Japan, and managed to spread it to 10 countries to explore Deep Tech to match Deep Issues. As well as managing international teams and businesses in Leave a Nest, he also developed a lot of international PoCs and collaborative researches between MNC and startup and different startups, so called international co-creation activities.
